naltrexone has been researched along with aspartic acid in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (37.50) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Faden, AI; Yum, SW | 1 |
Faden, AI; Graham, SH; Newman, A; Shimizu, H; Weinstein, P | 1 |
Chen, C; de Riel, JK; DesJarlais, RL; Li, JG; Liu-Chen, LY; Matecka, D; Rice, K; Yin, J; Zhang, Y | 1 |
Lisi, TL; Sluka, KA; Vance, CG | 1 |
Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R | 1 |
Ashenhurst, JR; Hutchison, KE; Morrow, AL; Ray, LA | 1 |
Berrettini, W; Gordon, AJ; Leong, SH; Lynch, KG; O'Brien, CP; Oslin, DW; Rukstalis, M | 1 |
Kayashima, S; Nagase, H; Oka, JI; Saitoh, A; Soda, A; Yamada, M; Yoshizawa, K | 1 |
3 trial(s) available for naltrexone and aspartic acid
Article | Year |
---|---|
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Topics: Acamprosate; Adult; Alcoholism; Alleles; Amino Acid Substitution; Asparagine; Aspartic Acid; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Genetic Carrier Screening; Genetic Markers; Genotype; Homozygote; Humans; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Prognosis; Receptors, Opioid, mu; Taurine; Temperance; Treatment Outcome | 2008 |
Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Amino Acid Substitution; Aspartic Acid; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Pregnanolone; Receptors, Opioid, mu; Young Adult | 2010 |
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Asparagine; Aspartic Acid; Double-Blind Method; Drug Administration Schedule; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Polymorphism, Single Nucleotide; Recurrence; Treatment Outcome | 2015 |
5 other study(ies) available for naltrexone and aspartic acid
Article | Year |
---|---|
Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia.
Topics: Animals; Aspartic Acid; Dibenzocycloheptenes; Dizocilpine Maleate; Humans; Ischemia; Male; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Rabbits; Spinal Cord; Time Factors | 1990 |
Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia.
Topics: Animals; Aspartic Acid; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Glycine; Hippocampus; Ischemic Attack, Transient; Kinetics; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Reperfusion; Stereoisomerism; Taurine; Time Factors | 1993 |
ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone.
Topics: Animals; Aspartic Acid; Carboxylic Acids; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Ligands; Morphine; Mutagenesis, Site-Directed; Naltrexone; Protein Binding; Rats; Receptors, Opioid, mu | 1999 |
High-frequency, but not low-frequency, transcutaneous electrical nerve stimulation reduces aspartate and glutamate release in the spinal cord dorsal horn.
Topics: Animals; Arthritis, Experimental; Aspartic Acid; Carrageenan; Chromatography, High Pressure Liquid; Glutamic Acid; Joints; Microdialysis; Naltrexone; Narcotic Antagonists; Posterior Horn Cells; Rats; Rats, Sprague-Dawley; Transcutaneous Electric Nerve Stimulation | 2005 |
A delta opioid receptor agonist, KNT-127, in the prelimbic medial prefrontal cortex attenuates glial glutamate transporter blocker-induced anxiety-like behavior in mice.
Topics: Amino Acid Transport System X-AG; Animals; Anti-Anxiety Agents; Anxiety; Aspartic Acid; Drug Interactions; gamma-Aminobutyric Acid; Glutamic Acid; Male; Mice; Microinjections; Morphinans; Naltrexone; Prefrontal Cortex; Receptors, Opioid, delta | 2018 |